Spyre Therapeutics, Inc. SYRE Gain (loss) on disposal of assets
Gain (loss) on disposal of assets at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s gain (loss) on disposal of assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s gain (loss) on disposal of assets?
- Spyre Therapeutics, Inc. (SYRE) reported gain (loss) on disposal of assets of $30M in Q1 2026.
- What does gain (loss) on disposal of assets mean?
- Gains or losses recognized on the disposal of businesses, property, equipment, investments, or other assets at prices above or below their carrying value.